Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

What are the prospects for a universal influenza vaccine?

Nature Medicine volume 5, pages 1119–1120 (1999)Cite this article

Abstract

The present influenza vaccines are good, but not good enough. New vaccination approaches are being developed with emphasis on minor viral antigens that may provide broader immunity (pages 1157–1163).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Surface antigens of the influenza A virus virion.

References

  1. Neirynck, et al. A universal Influenza A vaccine based on the extracellular domain of the M2 protein. Nature Med. 5 1157– 1163 (1999).

    Article  CAS  Google Scholar 

  2. Kilbourne, E.D., Johansson, B.E., & Grajowe, B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc. Natl. Acad. Sci. USA 87 786–790 (1990).

    Article  CAS  Google Scholar 

  3. Zebedee, S.L. & Lamb, R.A. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J. Virol. 62, 2762–2772 (1988).

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Ogra, P.L. et al. Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans. J. Infect. Dis. 135, 499–506 (1977).

    Article  CAS  Google Scholar 

  5. Kilbourne, E.D. et al. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 13, 1799–1803 (1995).

    Article  CAS  Google Scholar 

  6. Slepushkin, V.A. et al. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 13, 1399–1402 (1995).

    Article  CAS  Google Scholar 

  7. Frace, A.M., Klimov, A.I., Rowe, T., Black R.A. & Katz, J.M. Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 17, 2237 –2244 (1999).

    Article  CAS  Google Scholar 

  8. Kilbourne, E.D. in Influenza Bulletin. European Scientific Working Group on Influenza (ESWI). 3 Gardner-Caldwell Communications, (Macclesfield, UK, 1999).

    Google Scholar 

  9. Dowdle, R.W. Influenza anti-neuraminidase: the second best antibody. N. Engl. J. Med. 286, 136 (1972).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Microbiology and Immunology New York Medical College, Valhalla, 10595, New York, USA

    Edwin D. Kilbourne

Authors
  1. Edwin D. Kilbourne
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kilbourne, E. What are the prospects for a universal influenza vaccine?. Nat Med 5, 1119–1120 (1999). https://doi.org/10.1038/13436

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/13436

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing